Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Not yet recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 12Thoracic 9Gastrointestinal 7Gynecologic 5Other solid neoplasm 3Head & Neck 3Sarcoma 2Genitourinary 2Dermatologic 2NET 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Recurrence 1Endometrial Neoplasms 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × famitinib × Gynecologic × Clear all
NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

The First Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
43 enrolled
Gynecologic

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Tongji Hospital

Phase 2 Not yet recruiting
104 enrolled
Gynecologic

Ovarian Neoplasms

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
120 enrolled
Gynecologic

Cervical Cancer Metastatic

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
194 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡